Probiotic Blend for Celiac Disease

Launched by UNIVERSIDADE DO EXTREMO SUL CATARINENSE - UNIDADE ACADEMICA DE CIECIAS DA SAUDE · Dec 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a special combination of probiotics (which are helpful bacteria) to see if it can reduce symptoms and improve the quality of life for people with celiac disease. Celiac disease is an autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) can damage the intestines. The trial will involve 118 adult volunteers, aged 18 to 65, who have been diagnosed with celiac disease. Participants will be split into two groups: one will receive the probiotic blend, and the other will receive a placebo (a non-active substance). The study will last for 90 days and will include three visits where participants will fill out questionnaires about their symptoms and overall well-being.

To participate in this trial, individuals must provide written consent and be diagnosed with celiac disease by a doctor. However, those who have recently taken probiotics or have certain health conditions, like uncontrolled bowel diseases or heart problems, will not be eligible. This study is an opportunity for patients to potentially find relief from their symptoms while helping researchers learn more about the benefits of probiotics for celiac disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of Free and Informed Consent in writing, signed and dated;
• • Age according to the indicated population;
• • Patients diagnosed with celiac disease by a specialist physician.
• Exclusion Criteria:
• • History of daily consumption of probiotics, fermented milk and or yogurt;
• • subjects known to have demonstrated a prior reaction, including anaphylaxis, to any substance in the composition of the study product;
• • Subjects who have uncompensated blood pressure;
• • history of heart disease, including valvular heart disease or any implantable device;
• • subjects with active, uncontrolled bowel disease such as Crohn's disease or ulcerative colitis;
• • another clinical trial.